Title: Randomized open label multicentre phase III study of efficacy and safety in polycythermia versus subjects who are resilient to or intolerant of hydroxyurea: JAK inhibitor INC424 tablets versus best available care

Funder
Novartis Pharmaceuticals UK Ltd

Principal Investigator

Project Details
Net value award figure for Cardiff University: £7,590.00
Start date: 30/03/2011
End date: 31/03/2017

Last updated on 2020-14-08 at 09:45